8:00-8:30 |
Registration and Coffee |
8:30-9:15 |
State of the Neurotechnology Industry: 2022
James Cavuoto, Editor and Publisher, Neurotech Reports
Neurotech Business Report Editor James Cavuoto provides his insights and observations on the state of the neurotechnology industry. He surveys changes in the competitive landscape that have occurred over the years, the most significant events of the last year, and challenges confronting the industry in years ahead. |
9:15-10:00 |
Keynote Address |
10:00-10:30 |
Refreshment Break |
10:30-11:15 |
Neurotech Investment Outlook: Is the Gold Rush Over?
Jeremy Koff, Senior Consulting Editor, Neurotech Reports, Moderator
In the last few years, we've seen a considerable amount of VC investment in neurotech startups. But what will be the effect of more uncertain ecomomic conditions? Our panel of investment professionals will offer their insights. |
11:15-12:00 |
DBS Goes Deep: New Indications Emerge for Neuromodulation Therapies
James Cavuoto, Editor, Neurotech Reports, Moderator
Once restricted to treating movement disorders such as Parkinson's disease, deep-brain stimulation now stands to penetrate a range of new disorders. Abbott's reentry in the depression market sends a strong signal that DBS will be a key therapy for treating psychiatric disorders. Our panel of experts will discuss the possibilities. |
12:00-1:30 |
Luncheon, Sponsored by Cirtec Medical |
1:30-3:00 |
Neurotechnology Entrepreneur Panel
James Cavuoto, Editor, Neurotech Reports, Moderator
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets. |
3:00-3:30 |
Refreshment Break |
3:30-4:15 |
Sacred Ground: Privacy, Security, and Ethics in Neurotech
Jo Jo Platt, Contributing Editor, Neurotech Reports, Moderator
Marcus Gerhardt, CEO, Blackrock Neurotech
Rob Barnes, Principal Consultant, Amazon Web Services
This panel features a roundtable discussion to help investors evaluate a technology, founders to learn what's expected, and developers to understand the considerations that need to be baked in to every device. |
4:15-5:00 |
Overcoming Bias: Neurotech Therapies Seek to Penetrate Pharma Markets
Susan Schaeffer, Consulting Editor, Neurotech Reports, Moderator
The recent controversy surrounding failed drug trials for Alzheimer's and the dubious claims of the amyloid hypothesis highlights some of the bias neuromodulation vendors have had to confront when trying to penetrate a market dominated by big pharma. In this session, we'll explore some of the strategies device firms can employ to overcome the inherent bias that still exists.
|
5:00-7:00 |
Cocktail Reception, Sponsored by MST
|
|
|
8:00:8:30 |
Registration and Coffee |
8:30-9:15 |
Facing the Public: An Editorial Perspective
James Cavuoto, Editor and Publisher, Neurotech Reports, Moderator
Jeremy Koff, Senior Consulting Editor, Neurotech Reports
Jo Jo Platt, Contributing Editor, Neurotech Reports
In this session, Neurotech Reports team of editors will offer their views on recent controversies facing the neuromodulation industry, including ethical concerns, dealing with bad press, and legislative and regulatory developments.
|
9:15-10:00 |
Keynote Address
|
10:00-10:30 |
Coffee Break
|
10:30-11:15 |
Reimbursement Outlook: CMS Opens the Door for Neurotech Therapies
Jeremy Koff, Senior Consulting Editor, Neurotech Reports, Moderator
After a disappointing decision to repeal the Medicare Coverage of Innovative Technology program, CMS has offered guidance on constructing a replacement that would achieve similar results. And the several new codes for implanted and noninvasive therapies have emerged to help shorten the commercialization path for neurotech startups. Our panel of experts will discuss the reimbursement outlook for neurotech in this session.
|
11:15-12:00 |
Fixing What's Broke: Neurorehabilitation Devices Reach the Market
Jo Jo Platt, Contributing Editor, Neurotech Reports, Moderator
Jon Sakai, Director, Commercialization, Cionic
When the FDA approved MicroTransponder's Vivistim stroke therapy last year, it ended the drought that followed the Northstar EVEREST trial failure in 2009. In this panel, we'll examine some of the many new implantable and wearable neurorehabilitation therapies reaching the market. |
12:00-1:30 |
Luncheon, Sponsored by Cirtec Medical
Presentation of 2022 Gold Electrode Awards |
1:30-3:00 |
Neurotechnology Entrepreneur Panel
James Cavuoto, Editor, Neurotech Reports, Moderator
Luca Ravagnan, Ph.D., CEO, WISE Srl
|
3:00-3:30 |
Refreshment Break |
3:30-4:15 |
Reinventing the Wheel: Neurotech Startups Outsource Key Components
James Cavuoto, Editor, Neurotech Reports, Moderator
Andrew Kelly, Director of Applications Engineering, Cirtec Medical
Neurotech startups can save a considerable amount of time and expense by taking advantage of suppliers of key components such as power sources, interconnects, enclosures, and leads. In this session, we'll discuss the tradeoffs that entrepreneurs and their investors confront when making build or buy decisions. |
4:15-5:00 |
Spreading the Pain: Neuromodulation Vendors Stake Out New Ground
Jeremy Koff, Senior Consulting Editor, Neurotech Reports, Moderator
The market for treating chronic pain continues to be the largest segment of the neuromodulation industry, but vendors of SCS, PNS, and noninvasive devices are offering numerous therapeutic options for treating different types of pain. In this session, we'll explore the outlook for new targets and stimulation regimens. |
5:00-7:00 |
Cocktail Reception, Sponsored by MST |
|
|
